Elan finishes Prothena demerger; FDA boss blasts autism treatments;

Conversations on Twitter :

 @FierceBiotech: Add a drop of blood, and this tiny Dx device tests 50 things at once. Story | Follow @FierceBiotech

@JohnCFierce: Halozyme gets $8M upfront and a bunch of potential biobucks in drug delivery collab with Pfizer. Release | Follow @JohnCFierce

@RyanMFierce: Halozyme rebounds with $8M Pfizer biologics pact. More | Follow @RyanMFierce

An FDA advisory panel voted 8-5 against a drug from Hemispherix Biopharma ($HEB) for treating chronic fatigue syndrome. Article

> Irish pharma company Elan ($ELN) has wrapped the demerger of its drug discovery business into a new company called Prothena. Release

> Cubist ($CBST) submitted a supplemental NDA for approval of Entereg for use in speeding GI recovery after bowel surgeries. Release

> Bloomberg reported on treatments for autism that might border on fraud. Item

Pharma News

@FiercePharma: Smaller players looking for expansion deals, too. News | Follow @FiercePharma

> Sanofi animal health deal puts it in India. More

> India vaccinemakers see China undercutting them. Story

> EMA having second thoughts about Merck's Tredaptive. Item

Medical Device News

 @FierceMedDev: St. Jude faces escalation of shareholder lawsuits over Durata leads. Article | Follow @FierceMedDev

@MarkHFierce: Nanostim says it successfully implanted leadless cardiac pacers into 11 patients in the Czech Republic. Major progress. News | Follow @MarkHFierce

 @DamianFierce: Critical Diagnostics has inked distribution deals for its heart test with Quest ($DGX) and LabCorp ($LH). More | Follow @DamianFierce

> Invacare unloads med supplies unit to AssuraMed for $150M. Story

> Cincinnati Children's/Ben-Gurion U back three pediatric device projects. Item

> Illumina soars on fresh Roche buyout rumors. Report

And Finally… Happy holidays! We'll resume breaking news coverage on Dec. 26 and send your next issue of FierceBiotech on Jan. 2.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.